Overall ACRS gets a fundamental rating of 3 out of 10. We evaluated ACRS against 191 industry peers in the Pharmaceuticals industry. While ACRS seems to be doing ok healthwise, there are quite some concerns on its profitability. ACRS is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

ACRS had negative earnings in the past year.
In the past year ACRS has reported a negative cash flow from operations.
In the past 5 years ACRS always reported negative net income.
In the past 5 years ACRS always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of ACRS (-80.71%) is worse than 74.35% of its industry peers.
ACRS has a worse Return On Equity (-117.97%) than 64.92% of its industry peers.

		Industry Rank	Sector Rank
ROA	-80.71%
ROE	-117.97%
ROIC	N/A

ROA(3y)-46.3%

ROA(5y)-49.43%

ROE(3y)-61.73%

ROE(5y)-73.31%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a Gross Margin value of 3.98%, ACRS perfoms like the industry average, outperforming 50.79% of the companies in the same industry.
ACRS's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for ACRS so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	3.98%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-15.2%

GM growth 5Y35.7%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ACRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ACRS has been increased compared to 1 year ago.
Compared to 5 years ago, ACRS has more shares outstanding
There is no outstanding debt for ACRS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

ACRS has an Altman-Z score of -2.89. This is a bad value and indicates that ACRS is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.89, ACRS is doing worse than 60.73% of the companies in the same industry.
There is no outstanding debt for ACRS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-2.89

ROIC/WACCN/A

WACC9.4%

2.3 Liquidity

ACRS has a Current Ratio of 3.92. This indicates that ACRS is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.92, ACRS perfoms like the industry average, outperforming 59.69% of the companies in the same industry.
ACRS has a Quick Ratio of 3.92. This indicates that ACRS is financially healthy and has no problem in meeting its short term obligations.
ACRS's Quick ratio of 3.92 is fine compared to the rest of the industry. ACRS outperforms 61.26% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.92
Quick Ratio	3.92

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ACRS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -165.38%.
ACRS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -41.87%.
ACRS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 34.65% yearly.

EPS 1Y (TTM)-165.38%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-9.09%

Revenue 1Y (TTM)-41.87%

Revenue growth 3Y40.43%

Revenue growth 5Y34.65%

Sales Q2Q%-24.09%

3.2 Future

The Earnings Per Share is expected to grow by 8.25% on average over the next years. This is quite good.
ACRS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 24.44% yearly.

EPS Next Y64.01%

EPS Next 2Y26.24%

EPS Next 3Y15.75%

EPS Next 5Y8.25%

Revenue Next Year-27.07%

Revenue Next 2Y-17.95%

Revenue Next 3Y-8.23%

Revenue Next 5Y24.44%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ACRS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACRS. No positive earnings are expected for the next year.